OBJECTIVES: Colorectal cancer (CC) in the structure of cancer morbidity and mortality of the population of Russia occupies a leading position and has a high rate of growth. Aim of the study was to assess the annual costs of drug therapy in Moscow of patients with CC.

METHODS: We have constructed an analytical model, taking into account the data of Cancer Register for 2015-2016, as well as the literature sources.

RESULTS: We have estimated that among patients with CC, 94% are newly diagnosed patients, and 6% are patients continuing therapy. The costs of drug therapy (DT) of these groups of patients is 80 and 20% of all DT CC costs, respectively. Among the new patients, 13% have metastatic cancer, 87% - non-metastatic, costs for them equal to 58 and 22% of total costs for DT of CC, respectively. The percentage of patients is as follows: 70% - with localization of metastases to retroperitoneal lymph nodes, peritoneum, bone or multiple lung metastases; 30% - with isolated resectable or potentially resectable metastases in the liver and (or) in the lungs. The first group of patients costs 41%, the second - 5% of all costs of DT for CC. Among patients with non-metastatic cancer, 7.52% have stage 0-1 disease, 38.25% - 1, 24.00% - 2 and 30.23% - 3. In stages 0-1 and 1, patients are only observed, these groups do not cause costs of DT. The cost of DT in patients in stages 2 and 3 is 11% of the total cost of DT in patients with CC.

CONCLUSIONS: The cost structure for DT of patients with CC in Moscow shows that the most expensive is the treatment of patients with metastases to retroperitoneal lymph nodes, peritoneum, bone or multiple metastases to the lungs (41% of all costs for DT of CC).